Drug Profile
Vemurafenib prodrug - HEC Pharm
Latest Information Update: 08 Oct 2021
Price :
$50
*
At a glance
- Originator HEC Pharm
- Class 2 ring heterocyclic compounds; Antineoplastics; Chlorobenzenes; Fluorobenzenes; Pyridines; Pyrroles; Small molecules; Sulfonamides
- Mechanism of Action Proto oncogene protein b raf inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Malignant melanoma
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for preclinical development in Malignant-melanoma in China
- 03 Nov 2015 Preclinical trials in Malignant melanoma in China (unspecified route) (HEC Pharm, October 2015)